Gemcitabine–cisplatin versus MVAC chemotherapy for urothelial carcinoma: a nationwide cohort study | Scientific Reports
Bladder cancer
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). | Semantic
Optimising dose-dense regimens for early breast cancer | Cancer World Archive
Response rates to first-line therapy for metastatic urothelial... | Download Scientific Diagram
Dose-Dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin With or Without Panitumumab in Patients With Advanced Urothelial Carcinoma: Multicenter, Randomized, French Unicancer GETUG/AFU 19 Study - Clinical Genitourinary Cancer
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC - Medical Conferences
ESMO 2021: Dose-Dense Methotrexate, Vinblastine, Doxorubicin and Cisplatin or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with MIBC: GETUG/AFU VESPER V05 Phase III Trial
Open-label phase II to evaluate the efficacy of NEoadjuvant dose-dense MVAC In cOmbination with durvalumab and tremelimumab in muscle-invasive urothelial carcinoma: NEMIO - ScienceDirect
Dose dense MVAC prior to radical cystectomy: a real-world experience | Request PDF
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03) - ScienceDirect
Significant PFS Improvement at 3 Years with Neoadjuvant dd-MVAC
Randomized Phase III Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin, or Gemcitabine and Cisplatin as Perioperative Chemotherapy for Patients with Muscle-invasive Bladder Cancer. Analysis of the GETUG/AFU V05 VESPER Trial ...
ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer: AURA Trial
Dose-Dense (DD)-MVAC for Bladder Cancer | ChemoExperts
ESMO 2021: Avelumab as the Basis of Neoadjuvant Chemotherapy Regimen in Platinum Eligible and Ineligible Patients with Non-Metastatic Muscle Invasive Bladder Cancer (NM-MIBC)
1616-Bladder/Urothelial neoad ddMVAC (dd methotrexate vinBLASTine DOXOrubicin ciSplatin) | eviQ
Understanding Systemic Chemotherapy Options in Bladder Cancer Part II: Chemotherapy Candidacy & Side Effects
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients wi
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Treatment Administration Schedule: Dose-Dense MVAC (every 14 days for... | Download Table
Adjuvant Rx high-risk urothelial carcinoma of the bladder - UpToDate
Prospective, open-label, randomized, phase III study of two dose-dense regimens MVAC versus gemcitabine/cisplatin in patients with inoperable, metastatic or relapsed urothelial cancer: a Hellenic Cooperative Oncology Group study (HE 16/03). | Semantic
Cancers | Free Full-Text | Refining the Characterization and Outcome of Pathological Complete Responders after Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer: Lessons from the Randomized Phase III VESPER (GETUG-AFU V05) Trial
PT0 after NAC: Implications for Bladder Sparing and Prognosis
